Purposes of Using Prodrugs
Introducing an inactive precursor into the patient's body solves several critical pharmacokinetic problems encountered by researchers when developing standard drugs.
Key objectives of this approach include:
- Improving pharmacokinetic properties of the parent drug. Chemical modification makes a molecule more stable or, conversely, more soluble.
- Enhancing absorption and bioavailability. Many active metabolites are poorly absorbed orally. Masking problematic functional groups significantly increases the fraction of the substance entering systemic circulation.
- Ensuring targeted delivery to the site of action. Prodrugs bypass various tissue barriers (such as the blood-brain barrier) that normally block active compounds.
Mechanism of Action: From Precursor to Active Form
The fundamental principle of any prodrug is that it lacks pharmacological activity upon administration. The therapeutic effect develops only after the molecule undergoes structural modification inside the body.
The conversion of the inactive precursor into an active compound (or active metabolite) occurs via normal metabolic pathways. Activation most commonly occurs through:
- Various types of hydrolysis in tissues and blood plasma.
- Hepatic biotransformation during first-pass metabolism through liver enzyme systems.
Example 1: ACE Inhibitors and the Absorption Problem
A classic example of the prodrug concept in cardiology is the development of enalapril (Enalaprilum).
Chemically, the molecule contains a specific carboxyl group. The main issue is that the active metabolite itself—enalaprilat—has extremely poor gastrointestinal absorption (only about 10% of the ingested dose is absorbed).
The solution was designing a prodrug: oral enalapril demonstrates an absorption rate of approximately 60%. Once in the bloodstream, it undergoes hydrolysis, releasing active enalaprilat to exert the therapeutic effect.
Example 2: Valacyclovir and Active Transport
In antiviral therapy, the prodrug concept is brilliantly illustrated by valacyclovir.
Structurally, this drug combines an acyclovir molecule attached to a valine amino acid residue. This minor modification fundamentally alters the intestinal absorption mechanism.
Unlike standard acyclovir, valacyclovir is recognized by the body as a peptide and serves as a substrate for intestinal oligopeptide transporters. Through active transport mechanisms, drug bioavailability increases by more than 30%. Subsequently, the molecule undergoes hepatic biotransformation, converting into the active antiviral compound.
Example 3: Levodopa and Crossing CNS Barriers
Delivering drugs to the central nervous system is one of the most challenging tasks due to the tight blood-brain barrier (BBB).
Treatment of certain neurological disorders requires raising dopamine (Dopaminum) levels in the brain. However, dopamine itself cannot cross the BBB.
The pharmacological solution is levodopa (Levodopa). As an inactive precursor, levodopa successfully crosses from the bloodstream into the central nervous system tissues. Inside the brain, the molecule is acted upon by the enzyme DOPA decarboxylase, converting levodopa directly into active dopamine at the required site of action.